Trial design
This was a single-center, randomized, controlled, patient and outcome assessor-blinded trial. Patients were consecutively recruited from Beijing Tiantan Hospital, Capital Medical University from January 2021 to August 2021. Ethical approval for this study (KY2020-150–02) was provided by the Institutional Review Board of Beijing Tiantan Hospital, Capital Medical University, Beijing, China on January 17, 2021, and written informed consent was obtained from all patients. The trial was registered before patient enrollment at clinicaltrials.gov (31/12/2020, NCT04691128). The report follows the guideline for reporting parallel group randomized Consolidated Standards of Reporting Trials (CONSORT) 2010.